Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Amazon Explores AI Content Marketplace With Media Publishers 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
 Services - EconoTimes)
RANCHO CORDOVA, Calif., March 14, 2018 -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that its ThermoGenesis device subsidiary has signed a license agreement with IncoCell Tianjin Ltd., a wholly-owned subsidiary of China-based Boyalife Group, for CAR-T related and other cellular processing CDMO services. Pursuant to the terms of the agreement, ThermoGenesis has granted IncoCell an exclusive license to purchase and use, at a discounted purchase price, X-Series™ cellular processing research devices, consumables and kits for use in the conduct of CDMO operations in certain Asia Pacific countries. In exchange, ThermoGenesis is entitled to a percentage of IncoCell’s gross contract development revenues, including any potential upfront payments, future milestones or royalty payments.
“China is among the leading markets for CAR-T developers, and together with the U.S., represent the two countries with the highest number of ongoing CAR-T clinical trials,” said Dr. Chris Xu, chief executive officer of Cesca. “This agreement with IncoCell signifies our first CDMO collaboration, and is consistent with our goal of expanding beyond off-the-shelf cellular processing solutions into higher-value contract manufacturing and development services. Moving forward, we plan to pursue additional CDMO collaborations in selected markets while executing global distribution and other strategic partnering agreements for our highly differentiated X-Series line of products.”
Territories covered under the IncoCell agreement consist of the People’s Republic of China, Japan, South Korea, Taiwan, Hong Kong, Macau, Singapore, Malaysia, Indonesia and India.
About IncoCell Tianjin, Ltd.
Founded in 2015, IncoCell is a wholly-owned subsidiary of China-based Boyalife Group. The facility, which is headquartered in Tianjin, China, occupies 160,000 square feet of laboratory space dedicated to the contract development and manufacture of cellular products for immuno-oncology.
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress™ platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]
